CSBio CSBio

X
[{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI And AstraZeneca Achieve Collaboration Milestone With Novel AI-Generated Chronic Kidney Disease Target","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"BenevolentAI"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            AI-generated target was identified through Benevolent Platform® and AstraZeneca's scientific expertise and rich datasets. The Benevolent Platform® predicted this novel target, which was subsequently biologically validated through AstraZeneca's rigorous experimental testing.

            Lead Product(s): Undisclosed

            Therapeutic Area: Nephrology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: AstraZeneca

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 27, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY